CTRI/2024/05/067542
Not yet recruiting
Phase 4
Efficacy and Safety of Fluvoxamine alone and in combination with L-Methyltetrafolate in patients with Obsessive Compulsive Disorder - nil
PT B.D Sharma UHS Rohtak0 sites0 target enrollmentTBD
Overview
- Phase
- Phase 4
- Intervention
- Not specified
- Conditions
- Health Condition 1: F42- Obsessive-compulsive disorder
- Sponsor
- PT B.D Sharma UHS Rohtak
- Status
- Not yet recruiting
- Last Updated
- last year
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- •1\)Age 18\-65 years
- •2\)Patient fulfilling the criteria of OCD as
- •per ICD\-11 any severity YBOCS score more than
- •3\) Willing to participate and give
- •informed consent
Exclusion Criteria
- •1\) Current diagnosis of OCD with
- •psychotic features or any other
- •psychiatric diagnosis in the past
- •2\) Patient with a history of any
- •chronic physical illness
- •3\) Current psychoactive substance use
- •Pregnant and lactating women
Outcomes
Primary Outcomes
Not specified
Similar Trials
Not yet recruiting
Not Applicable
Comparison of Drugs, Fluvoxamine and Fluoxetine in patients with OCD in terms of efficacy and effect on clinical and biochemical parameters.Health Condition 1: F42- Obsessive-compulsive disorderCTRI/2023/01/048722Government Medical College and Hospital, Chandigarh
Recruiting
Phase 4
A longitudinal study of the fluvoxamine treatment for the structural and functional connectivity between the orbitofrontal cortex and the ventral striatum in obsessive compulsive disorderJPRN-jRCT1051180029akamae takashi30
Recruiting
Not Applicable
A longitudinal study of the fluvoxamine treatment for the structural and functional connectivity between the orbitofrontal cortex and the ventral striatum in obsessive compulsive disorderobsessive-compulsive disorderJPRN-UMIN000022815Department of Psychiatry, Graduate School of Medical Science, Kyoto Prefectural University of Medicine,30
Completed
Phase 3
Fluvoxamine in Long COVIDong or Post COVID syndrome.Post COVID-19 condition occurs in individuals with a history of probable or confirmed SARS CoV-2 infection, usually 3 months from the onset of COVID-19 with symptoms and that last for at least 2 months and cannot be explained by an alternative diagnosis.U09.9IRCT20220526054990N1Artesh University of Medical Sciences96
Active, not recruiting
Not Applicable
The effect of fluvoxamine and ciprofloxacin on the pharmacokinetics and pharmacodynamics of nabumetone: A three-phase double-blind placebo-controlled cross-over study.Pharmacokinetics and pharmacodynamics, healthy volunteer trialEUCTR2008-007647-14-FITurku University Hospital12